提醒企业对接-路演巴克莱将主办美敦力公司（MDT）-波士顿

Matt Miksicjoined Barclays in July 2022 with over 20years of experience covering U.S. Medical Supplies andDevices. Matt previously covered Med Tech at MorganStanley, PiperJaffray,UBS and most recently at CreditSuisse. Prior to covering Med Tech, Matt was a member ofthe Morgan Stanley EnterpriseSoftwareresearch team,and prior to joining Morgan Stanley was a senior managerwith Arthur Andersen in its business consulting divisionand spent five years with asoftwarestart-up. Matt holds aB.A. in computer science from Rutgers University and anM.B.A. from the Leonard N. Stern School of Business atNew York University.View Analyst PageU.S. Medical Supplies & DevicesThis event is intended for Barclays institutional investor clients only. This event is strictly and solelyfor the benefit of the intended recipients. Please do not forward this invitation to any other partywithout written consent from Barclays Research. Barclays' Investment Bankers are prohibited fromattending this event. Participant comments are not for attribution.If your firm is in-scope for research unbundling under MiFID II and you require further informationregarding pricing to participate in this Barclays Research content event, please contact your salesBarclays Events Terms of Service | Barclays Events Privacy NoticeThis communication has been prepared by Barclays.“Barclays” means any entity within the Barclays Group of companies, where “Barclays Group” meansBarclays Bank PLC, Barclays PLC and any of their subsidiaries,affiliates,ultimate holding companyand any subsidiaries oraffiliatesof such holding company.BARCLAYS IS A FULL SERVICE INVESTMENT BANK. In the normal course ofofferinginvestment bankingproducts and services to clients, Barclays may act in several capacities (including issuer, marketmaker and/or liquidity provider, underwriter, distributor, index sponsor, swap counterparty andcalculation agent) simultaneously with respect to a product, giving rise to potential conflicts ofinterest which may impact the performance of a product.Barclays may at any time acquire, hold or dispose of long or short positions (including hedging andtrading positions) and trade or otherwiseeffecttransactions for their own account or the account oftheir customers in the products referred to herein which may impact the performance of a product. Matt Miksic+1 212 526 9189BCI, USrepresentative.Disclaimer:BARCLAYSCONFLICTS OF INTERESTBARCLAYS POSITIONS FOR INFORMATION ONLYTHIS DOCUMENT IS PROVIDED FOR INFORMATION PURPOSES ONLY AND IT IS SUBJECT TO CHANGE.This information has been prepared by the Research Department within the Investment Bank ofBarclays. The information, analytic tools, and/or models referenced herein (and any reports or resultsderived from their use) are intended for informational purposes only. Barclays has no obligation toupdate this information and may cease provision of this information at any time and without notice.NO OFFERBarclays is notofferingto sell or seekingoffersto buy any product or enter into any transaction. Anyofferor entry into any transaction requires Barclays’ subsequent formal agreement which will besubject to internal approvals and execution of binding transaction documents. The productsmentioned may not be eligible for sale in some states or countries, nor suitable for all types ofinvestors. Without limitation to the foregoing, any transaction may also be subject to review byBarclays Group against its published Tax Principles.NO LIABILITYNeither Barclays nor any of its directors,officers,employees, representatives or agents, accepts anyliability whatsoever for any direct, indirect or consequential losses (in contract, tort or otherwise)arising from the use of this communication or its contents or reliance on the information containedherein, except to the extent this would be prohibited by law or regulation.NO ADVICEBarclays is not acting as a fiduciary. Barclays does not provide, and has not provided, any investmentadvice or personal recommendation to you in relation to any transaction and/or any related securitiesdescribed herein and is not responsible for providing or arranging for the provision of any generalfinancial, strategic or specialist advice, including legal, regulatory, accounting, model auditing ortaxation advice or services or any other services in relation to the transaction and/or any relatedsecurities described herein. Accordingly Barclays is under no obligation to, and shall not, determinethe suitability for you of the transaction described herein. You must determine, on your own behalf orthrough independent professional advice, the merits, terms, conditions and risks of any transactiondescribed herein.NOT A BENCHMARKThe information provided does not constitute a financial benchmark and should not be used as asubmission or contribution of input data for the purposes of determining a financial benchmark.SUSTAINABLE INVESTING RELATED RESEARCHThere is currently no globally accepted framework or definition (lega